Gilead Sciences’ remdesivir has been a crucial treatment for COVID-19 for months, but new data from a “gold standard” trial give a clearer picture of the med’s benefit. The drug, tested against placebo, improved recovery times, reduced chances of patients progressing to more severe stages of illness and significantly cut the risk of death in a subset of patients.
In a U.S. government-led, placebo-controlled, double-blinded study, patients on the drug recovered five days faster than those on placebo on average. Severe patients, who made up 86% of the trial, recovered seven days faster on average. The results show that the drug provides a major benefits to patients, their families and healthcare systems, Gilead CEO Daniel O’Day wrote in an open letter.